Activation	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
in	O
a	O
cyclosporin	O
A-resistant	O
pathway	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
the	O
immunosuppressive	O
drug	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
the	O
inactivation	O
of	O
the	O
Ca2+/calmodulin-dependent	B-protein
serine-threonine	I-protein
phosphatase	I-protein
calcineurin	B-protein
by	O
the	O
drug-immunophilin	B-protein
complex	I-protein
.	O

Inactive	O
calcineurin	B-protein
is	O
unable	O
to	O
activate	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
required	O
for	O
expression	O
of	O
the	O
interleukin	B-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
.	O

IL-2	B-protein
production	O
by	O
CsA-treated	B-cell_line
cells	I-cell_line
is	O
therefore	O
dramatically	O
reduced	O
.	O

We	O
demonstrate	O
here	O
,	O
however	O
,	O
that	O
NFAT	B-protein
can	O
be	O
activated	O
,	O
and	O
significant	O
levels	O
of	O
IL-2	B-protein
can	O
be	O
produced	O
by	O
the	O
CsA-resistant	O
CD28	B-protein
-signaling	O
pathway	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
both	O
multicopy	O
NFAT	B-protein
-and	O
IL-2	B-DNA
promoter-beta-galactosidase	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
could	O
be	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
/alpha-	O
CD28	B-protein
stimulation	O
,	O
and	O
this	O
activation	O
was	O
resistant	O
to	O
CsA	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
the	O
induction	O
of	O
a	O
CsA-resistant	B-protein
NFAT	I-protein
complex	I-protein
in	O
the	O
nuclear	O
extracts	O
of	O
peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
PMA	O
plus	O
alphaCD28	B-protein
.	O

Peripheral	B-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
stimulated	O
with	O
PMA	O
/alphaCD28	B-protein
produced	O
IL-2	B-protein
in	O
the	O
presence	O
of	O
CsA	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
NFAT	B-protein
can	O
be	O
activated	O
and	O
IL-2	B-protein
can	O
be	O
produced	O
in	O
a	O
calcineurin	B-protein
independent	O
manner	O
.	O

THs	NULL
JourNaL	NULL
or	NULL
BrorocicaL	NULL
CHEMISTRY	NULL
Vol	NULL
.	NULL

271	NULL
,	NULL
No	NULL
.	NULL

13	NULL
,	NULL
Issue	NULL
of	NULL
March	NULL
29	NULL
,	NULL
pp	NULL
.	NULL

7700-7704	NULL
,	NULL
1996	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Activation	NULL
of	NULL
Nuclear	NULL
Factor	NULL
of	NULL
Activated	NULL
T	NULL
Cells	NULL
in	NULL
a	NULL
Cyclosporin	NULL
A-resistant	NULL
Pathway*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
December	NULL
28	NULL
,	NULL
1995	NULL
)	NULL
Paritosh	NULL
Ghosh	NULL
#	NULL
§	NULL
,	NULL
Antonio	NULL
Sicat	NULL
,	NULL
Marco	NULL
Cippitelli	NULL
{	NULL
,	NULL
Jeff	NULL
Subleski1	NULL
,	NULL
Riitta	NULL
Lahesmaal	NULL
,	NULL
Howard	NULL
A	NULL
.	NULL

Young	NULL
?	NULL

,	NULL
and	NULL
Nancy	NULL
R.	NULL
Rice**	NULL
From	NULL
the	NULL
{	NULL
Laboratory	NULL
of	NULL
Experimental	NULL
Immunology	NULL
,	NULL
Division	NULL
of	NULL
Basic	NULL
Science	NULL
and	NULL
the	NULL
(	NULL
Biological	NULL
Carcinogenesis	NULL
Development	NULL
Program	NULL
,	NULL
SAIC	NULL
,	NULL
Frederick	NULL
,	NULL
Maryland	NULL
21702-1201	NULL
,	NULL
the	NULL
Department	NULL
of	NULL
Leukocyte	NULL
Biology	NULL
,	NULL
Syntex	NULL
Research	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
California	NULL
94304	NULL
,	NULL
and	NULL
the	NULL
**Molecular	NULL
Basis	NULL
of	NULL
Carcinogenesis	NULL
Laboratory	NULL
,	NULL
ABL-Basic	NULL
Research	NULL
Program	NULL
,	NULL
NCI-Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
Frederick	NULL
,	NULL
Maryland	NULL
21702-1201	NULL
The	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
the	NULL
immunosuppressive	NULL
drug	NULL
cyelosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
is	NULL
the	NULL
inactivation	NULL
of	NULL
the	NULL
Ca**/	NULL
calmodulin-dependent	NULL
serine-threonine	NULL
phosphatase	NULL
calcineurin	NULL
by	NULL
the	NULL
drug-immunophilin	NULL
complex	NULL
.	NULL

Inactive	NULL
calcineurin	NULL
is	NULL
unable	NULL
to	NULL
activate	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
gene	NULL
.	NULL

IL-2	NULL
production	NULL
by	NULL
CsA-treated	NULL
cells	NULL
is	NULL
therefore	NULL
dramatically	NULL
reduced	NULL
.	NULL

We	NULL
demonstrate	NULL
here	NULL
,	NULL
however	NULL
,	NULL
that	NULL
NFAT	NULL
can	NULL
be	NULL
activated	NULL
,	NULL
and	NULL
significant	NULL
levels	NULL
of	NULL
IL-2	NULL
can	NULL
be	NULL
produced	NULL
by	NULL
the	NULL
CsA-resistant	NULL
CD28-signaling	NULL
pathway	NULL
.	NULL

In	NULL
transient	NULL
transfection	NULL
assays	NULL
,	NULL
both	NULL
multicopy	NULL
NFAT-	NULL
and	NULL
IL-2	NULL
promoter-B-galactosidase	NULL
reporter	NULL
gene	NULL
constructs	NULL
could	NULL
be	NULL
activated	NULL
by	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
/a	NULL
«	NULL
CD28	NULL
stimulation	NULL
,	NULL
and	NULL
this	NULL
activation	NULL
was	NULL
resistant	NULL
to	NULL
CsA	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
showed	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
CsA-resistant	NULL
NFAT	NULL
complex	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
«	NULL
CD28	NULL
.	NULL

Peripheral	NULL
blood	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA/aCD28	NULL
produced	NULL
IL-2	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
NFAT	NULL
can	NULL
be	NULL
activated	NULL
and	NULL
IL-2	NULL
can	NULL
be	NULL
produced	NULL
in	NULL
a	NULL
calcineurin	NULL
independent	NULL
manner	NULL
.	NULL

Nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
is	NULL
required	NULL
for	NULL
IL-2	NULL
production	NULL
after	NULL
antigenic	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Upon	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
an	NULL
NFAT-containing	NULL
protein	NULL
complex	NULL
appears	NULL
in	NULL
the	NULL
nucleus	NULL
and	NULL
recognizes	NULL
two	NULL
or	NULL
more	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

The	NULL
complex	NULL
is	NULL
composed	NULL
of	NULL
a	NULL
preexisting	NULL
cytoplasmic	NULL
component	NULL
,	NULL
which	NULL
translocates	NULL
to	NULL
the	NULL
nu-cleus	NULL
,	NULL
and	NULL
an	NULL
inducible	NULL
nuclear	NULL
component	NULL
composed	NULL
of	NULL
members	NULL
of	NULL
the	NULL
AP1	NULL
family	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

Translocation	NULL
of	NULL
the	NULL
cytoplasmic	NULL
component	NULL
involves	NULL
Ca	NULL
``	NULL
*-induced	NULL
activation	NULL
of	NULL
the	NULL
calcium/	NULL
calmodulin-dependent	NULL
serine/threonine	NULL
phosphatase	NULL
calcineurin	NULL
(	NULL
5	NULL
,	NULL
7	NULL
)	NULL
.	NULL

Inactivation	NULL
of	NULL
calcineurin	NULL
by	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
CsA	NULL
or	NULL
FK506	NULL
results	NULL
in	NULL
the	NULL
blockage	NULL
of	NULL
translocation	NULL
and	NULL
inhibition	NULL
of	NULL
IL-2	NULL
production	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

CD28	NULL
is	NULL
a	NULL
T	NULL
cell	NULL
surface	NULL
molecule	NULL
that	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
as	NULL
*	NULL
This	NULL
research	NULL
was	NULL
sponsored	NULL
in	NULL
part	NULL
by	NULL
NCI	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Department	NULL
of	NULL
Health	NULL
and	NULL
Human	NULL
Services	NULL
,	NULL
under	NULL
contract	NULL
with	NULL
ABL	NULL
and	NULL
SAIC	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
17834	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

§	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Laboratory	NULL
of	NULL
Experimental	NULL
Immunology	NULL
,	NULL
NCI-FCRDC	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bldg	NULL
.	NULL

560	NULL
,	NULL
Rm	NULL
.	NULL

31-30	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
21702	NULL
.	NULL

*The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
NFAT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
TK-Bgal	NULL
,	NULL
thymidine	NULL
kinase-B-galactosidase	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
18-acetate	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
HIV	NULL
,	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

a	NULL
coreceptor	NULL
in	NULL
the	NULL
optimal	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
9	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
major	NULL
effects	NULL
of	NULL
CD28	NULL
stimulation	NULL
is	NULL
increased	NULL
production	NULL
of	NULL
cytokines	NULL
,	NULL
such	NULL
as	NULL
IL-2	NULL
,	NULL
interferon	NULL
y	NULL
,	NULL
granulocyte	NULL
macrophage-colony	NULL
stimulating	NULL
factor	NULL
,	NULL
and	NULL
others	NULL
,	NULL
through	NULL
transcriptional	NULL
and	NULL
post-transcriptional	NULL
mechanisms	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
hallmarks	NULL
of	NULL
the	NULL
CD28	NULL
costimulation	NULL
is	NULL
its	NULL
insensitivity	NULL
to	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
CsA	NULL
and	NULL
FK506	NULL
(	NULL
10	NULL
,	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

We	NULL
reasoned	NULL
that	NULL
if	NULL
CD28	NULL
costimulation	NULL
results	NULL
in	NULL
IL-2	NULL
production	NULL
,	NULL
and	NULL
if	NULL
NFAT	NULL
is	NULL
required	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
,	NULL
there	NULL
must	NULL
be	NULL
a	NULL
CsA-resistant	NULL
pathway	NULL
for	NULL
activation	NULL
of	NULL
NFAT	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
NFAT	NULL
can	NULL
be	NULL
activated	NULL
in	NULL
a	NULL
CsA-resistant	NULL
manner	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
and	NULL
Tissue	NULL
Culture-Freshly	NULL
purified	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
CD3	NULL
cells	NULL
.	NULL

PMA	NULL
was	NULL
used	NULL
at	NULL
10	NULL
ng/ml	NULL
,	NULL
ionomycin	NULL
at	NULL
1	NULL
ug/ml	NULL
,	NULL
and	NULL
«	NULL
CD28	NULL
monoclonal	NULL
antibody	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Carl	NULL
H.	NULL
June	NULL
)	NULL
at	NULL
100	NULL
ng/ml	NULL
.	NULL

Cyclosporin	NULL
A	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
was	NULL
added	NULL
30	NULL
min	NULL
before	NULL
addition	NULL
of	NULL
the	NULL
other	NULL
stimuli	NULL
.	NULL

Plasmids-The	NULL
thymidine	NULL
kinase-B-galactosidase	NULL
(	NULL
TK-Bgal	NULL
)	NULL
reporter	NULL
plasmid	NULL
was	NULL
constructed	NULL
by	NULL
subcloning	NULL
a	NULL
HindlIIW/X/ol	NULL
fragment	NULL
containing	NULL
the	NULL
TK	NULL
promoter	NULL
from	NULL
the	NULL
pBLCAT2	NULL
vector	NULL
(	NULL
14	NULL
)	NULL
into	NULL
the	NULL
pEQ3	NULL
LacZ	NULL
plasmid	NULL
(	NULL
15	NULL
)	NULL
.	NULL

The	NULL
NFAT-TK-Ggal	NULL
plasmid	NULL
was	NULL
constructed	NULL
by	NULL
synthesizing	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
IL-2	NULL
distal	NULL
NFAT	NULL
site	NULL
(	NULL
AAAGAAAG-GAGGAAAAACTGTTTCATACAG	NULL
)	NULL
,	NULL
containing	NULL
HindIII	NULL
(	NULL
at	NULL
the	NULL
5	NULL
end	NULL
)	NULL
and	NULL
BamHI	NULL
(	NULL
at	NULL
the	NULL
3	NULL
'	NULL
end	NULL
)	NULL
restriction	NULL
sites	NULL
,	NULL
and	NULL
subcloning	NULL
into	NULL
the	NULL
TK-Bgal	NULL
plasmid	NULL
.	NULL

The	NULL
NFxB-TK-Bgal	NULL
reporter	NULL
plasmid	NULL
was	NULL
constructed	NULL
as	NULL
above	NULL
,	NULL
using	NULL
the	NULL
IgxB	NULL
sequence	NULL
(	NULL
ACAAGGGACTTTCCGCT	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
vectors	NULL
for	NULL
NFAT	NULL
,	NULL
and	NULL
for	NULL
dominant	NULL
negative	NULL
NFAT	NULL
,	NULL
(	NULL
16	NULL
)	NULL
were	NULL
generous	NULL
gifts	NULL
from	NULL
Dr.	NULL
Gerald	NULL
R.	NULL
Crabtree	NULL
.	NULL

The	NULL
pIL2-568	NULL
(	NULL
15	NULL
)	NULL
construct	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Christopher	NULL
B.	NULL
Wilson	NULL
)	NULL
was	NULL
generated	NULL
by	NULL
subcloning	NULL
the	NULL
HindIII	NULL
fragment	NULL
(	NULL
-568	NULL
to	NULL
+50	NULL
)	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
into	NULL
the	NULL
pEQ3	NULL
LacZ	NULL
plasmid	NULL
.	NULL

Transfection	NULL
and	NULL
B-Galactosidase	NULL
Assay-Cells	NULL
were	NULL
transfected	NULL
by	NULL
a	NULL
modified	NULL
DEAE-dextran	NULL
method	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
RPMI	NULL
containing	NULL
50	NULL
mm	NULL
Tris	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
resuspended	NULL
in	NULL
the	NULL
same	NULL
medium	NULL
at	NULL
a	NULL
density	NULL
of	NULL
8	NULL
X	NULL
10°/ml	NULL
.	NULL

An	NULL
aliquot	NULL
of	NULL
a	NULL
0.5-ml	NULL
cell	NULL
suspension	NULL
containing	NULL
appropriate	NULL
plasmids	NULL
was	NULL
added	NULL
to	NULL
0.5	NULL
ml	NULL
of	NULL
Tris-RPMI	NULL
containing	NULL
500	NULL
ug/ml	NULL
DEAE-dextran	NULL
.	NULL

The	NULL
aliquot	NULL
was	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
occasional	NULL
stirring	NULL
,	NULL
then	NULL
centrifuged	NULL
,	NULL
washed	NULL
once	NULL
with	NULL
Tris-RPML	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
5	NULL
ml	NULL
of	NULL
RPMI	NULL
(	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
)	NULL
and	NULL
plated	NULL
in	NULL
a	NULL
six-well	NULL
plate	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stimulated	NULL
after	NULL
24	NULL
h	NULL
and	NULL
harvested	NULL
for	NULL
B-galactosidase	NULL
assay	NULL
18	NULL
h	NULL
after	NULL
stimulation	NULL
.	NULL

When	NULL
multiple	NULL
stimulations	NULL
for	NULL
a	NULL
particular	NULL
plasmid	NULL
(	NULL
s	NULL
)	NULL
were	NULL
used	NULL
,	NULL
transfection	NULL
was	NULL
done	NULL
in	NULL
a	NULL
single	NULL
tube	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
divided	NULL
into	NULL
groups	NULL
depending	NULL
on	NULL
the	NULL
various	NULL
stimulations	NULL
.	NULL

B-Galactosidase	NULL
was	NULL
assayed	NULL
as	NULL
reported	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
results	NULL
were	NULL
expressed	NULL
as	NULL
activity	NULL
,	NULL
calculated	NULL
as	NULL
follows	NULL
:	NULL
(	NULL
A	NULL
;	NULL
,	NULL
,	NULL
/ug	NULL
of	NULL
protein	NULL
)	NULL
X	NULL
10°	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
(	NULL
EMSA	NULL
)	NULL
-The	NULL
preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
and	NULL
EMSA	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
oligonucleotides	NULL
used	NULL
were	NULL
:	NULL
IL-2	NULL
distal	NULL
NFAT	NULL
site	NULL
(	NULL
5'-AAA-GAAAGGAGGAAAAACTGTTTCATACAG-3	NULL
'	NULL
)	NULL
,	NULL
API	NULL
site	NULL
from	NULL
human	NULL
collagenase	NULL
gene	NULL
(	NULL
b'-agetATGAGTCAGACACCTCTGGCTTTCTGGA-AGG-3	NULL
'	NULL
)	NULL
,	NULL
SP1	NULL
site	NULL
from	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
5'-GATCGGGAG-GCGT	NULL
GGCCTGGGCGGCGACTGGGGAGTGGCGA-3	NULL
'	NULL
)	NULL
.	NULL

Antisera-Antiserum	NULL
«	NULL
NFAT	NULL
was	NULL
raised	NULL
against	NULL
a	NULL
peptide	NULL
that	NULL
is	NULL
7700	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Activation	NULL
of	NULL
NFAT	NULL
in	NULL
Presence	NULL
of	NULL
CsA	NULL
T701	NULL
25	NULL
A	NULL
B	NULL
;	NULL
,	NULL
2	NULL
DNFAT-TK-Bgal	NULL
20	NULL
E	NULL
TK-Bgal	NULL
ONFAT-TK-Bgat	NULL
>	NULL
1.6	NULL
15	NULL
N	NULL
TK-Bgal	NULL
2	NULL
a	NULL
&	NULL
10	NULL
as	NULL
5	NULL
a	NULL
|	NULL
_C	NULL
wom	NULL
_	NULL
,	NULL
F	NULL
}	NULL
,	NULL
.	NULL

f	NULL
,	NULL
__	NULL
--	NULL
1	NULL
Medium	NULL
PMA	NULL
PMACD28	NULL
PMAICD2ECsA	NULL
P	NULL
PICSA	NULL
C	NULL
*	NULL
a	NULL
O	NULL
NFAT-TK-Rgal	NULL
+	NULL
NFATe	NULL
T	NULL
s	NULL
MTK-Rgal	NULL
+NFATc	NULL
&	NULL
s	NULL
&	NULL
$	NULL
4	NULL
3	NULL
2	NULL
1	NULL
a	NULL
|	NULL
&	NULL
4	NULL
&	NULL
$	NULL
o	NULL
ib	NULL
Of	NULL
#	NULL
$	NULL
8	NULL
B	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Activation	NULL
of	NULL
an	NULL
NFAT-reporter	NULL
gene	NULL
construct	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
.	NULL

A	NULL
and	NULL
B	NULL
,	NULL
the	NULL
NFAT-TK-Ggal	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
and	NULL
TK-fBgal	NULL
constructs	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
that	NULL
were	NULL
subsequently	NULL
stimulated	NULL
with	NULL
medium	NULL
alone	NULL
,	NULL
PMA	NULL
,	NULL
PMA/eCD28	NULL
,	NULL
or	NULL
PMA/ionomycin	NULL
.	NULL

Wherever	NULL
indicated	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
CsA	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
30	NULL
min	NULL
.	NULL

Results	NULL
are	NULL
the	NULL
average	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
.	NULL

C	NULL
,	NULL
effect	NULL
of	NULL
overexpression	NULL
of	NULL
NFAT	NULL
,	NULL
on	NULL
NFAT-TK-Bgal	NULL
construct	NULL
.	NULL

NFAT-TK-Bgal	NULL
and	NULL
TK-Ggal	NULL
constructs	NULL
(	NULL
10	NULL
ug	NULL
each	NULL
)	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
along	NULL
with	NULL
NFAT	NULL
,	NULL
expression	NULL
vector	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
subsequently	NULL
stimulated	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
average	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
is	NULL
shown	NULL
here	NULL
.	NULL

highly	NULL
conserved	NULL
in	NULL
all	NULL
NFAT	NULL
proteins	NULL
described	NULL
to	NULL
date	NULL
.	NULL

The	NULL
peptide	NULL
is	NULL
found	NULL
in	NULL
the	NULL
Rel	NULL
homology	NULL
domain	NULL
,	NULL
and	NULL
its	NULL
sequence	NULL
is	NULL
NH	NULL
,	NULL
-SDIEL-RKGETDIGRKNTR	NULL
.	NULL

Antiserum	NULL
@	NULL
NFAT	NULL
,	NULL
,	NULL
was	NULL
raised	NULL
against	NULL
a	NULL
peptide	NULL
specific	NULL
to	NULL
NFAT	NULL
,	NULL
Its	NULL
sequence	NULL
is	NULL
VPAIKTEPSDEYEPSLI	NULL
(	NULL
sequence	NULL
in	NULL
murine	NULL
NFAT	NULL
,	NULL
but	NULL
the	NULL
antiserum	NULL
also	NULL
recognizes	NULL
the	NULL
human	NULL
protein	NULL
)	NULL
.	NULL

Cytokine	NULL
Testing-Human	NULL
IL-2	NULL
was	NULL
measured	NULL
by	NULL
ELISA	NULL
(	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
)	NULL
test	NULL
kits	NULL
from	NULL
Genzyme	NULL
Corp.	NULL
(	NULL
Cam-bridge	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

The	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
the	NULL
Clinical	NULL
Immunology	NULL
Services	NULL
Program	NULL
,	NULL
SAIC	NULL
,	NULL
NCI-FCRDC	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
.	NULL

RESULTS	NULL
Induction	NULL
of	NULL
NFAT	NULL
Activity	NULL
in	NULL
a	NULL
CsA-resistant	NULL
Pathway-To	NULL
investigate	NULL
whether	NULL
NFAT	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
CD28	NULL
costimu-lation	NULL
,	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
distal	NULL
NFAT	NULL
site	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
were	NULL
subcloned	NULL
into	NULL
a	NULL
TK-Bgal	NULL
reporter	NULL
gene	NULL
construct	NULL
,	NULL
designated	NULL
as	NULL
NFAT-TK-Bgal	NULL
.	NULL

This	NULL
construct	NULL
was	NULL
transfected	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
NFAT	NULL
activity	NULL
was	NULL
assayed	NULL
after	NULL
various	NULL
treatments	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

Since	NULL
we	NULL
were	NULL
looking	NULL
for	NULL
a	NULL
CsA-resistant	NULL
pathway	NULL
,	NULL
we	NULL
could	NULL
not	NULL
use	NULL
«	NULL
CD3	NULL
as	NULL
a	NULL
stimulus	NULL
,	NULL
because	NULL
one	NULL
of	NULL
the	NULL
pathways	NULL
it	NULL
activates	NULL
is	NULL
Ca	NULL
``	NULL
Therefore	NULL
,	NULL
we	NULL
chose	NULL
to	NULL
mimic	NULL
the	NULL
Ca**-independent	NULL
aspect	NULL
of	NULL
«	NULL
CD3	NULL
signaling	NULL
by	NULL
PMA	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
20	NULL
)	NULL
.	NULL

PMA	NULL
alone	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
reporter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
and	NULL
«	NULL
CD28	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
but	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
«	NULL
CD28	NULL
resulted	NULL
in	NULL
significant	NULL
activity	NULL
(	NULL
about	NULL
4-fold	NULL
induction	NULL
relative	NULL
to	NULL
the	NULL
vector	NULL
alone	NULL
)	NULL
.	NULL

Strikingly	NULL
,	NULL
nearly	NULL
all	NULL
of	NULL
this	NULL
(	NULL
PMA	NULL
+	NULL
«	NULL
CD28	NULL
)	NULL
-induced	NULL
activity	NULL
was	NULL
resistant	NULL
to	NULL
CsA	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
NFAT	NULL
activity	NULL
induced	NULL
by	NULL
PMA	NULL
+	NULL
ionomycin	NULL
was	NULL
essentially	NULL
completely	NULL
CsA-sensitive	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
well-known	NULL
Ca*	NULL
``	NULL
*-dependent	NULL
pathway	NULL
,	NULL
there	NULL
is	NULL
a	NULL
second	NULL
Ca**-independent	NULL
way	NULL
to	NULL
activate	NULL
NFAT	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
described	NULL
above	NULL
,	NULL
it	NULL
was	NULL
possible	NULL
that	NULL
the	NULL
assay	NULL
measured	NULL
some	NULL
other	NULL
unknown	NULL
factor	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
NFAT	NULL
sites	NULL
in	NULL
the	NULL
reporter	NULL
plasmid	NULL
rather	NULL
than	NULL
bona	NULL
fide	NULL
NFAT	NULL
activity	NULL
.	NULL

To	NULL
test	NULL
this	NULL
,	NULL
the	NULL
assays	NULL
were	NULL
repeated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cotransfected	NULL
NFAT	NULL
,	NULL
,	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
results	NULL
of	NULL
others	NULL
(	NULL
16	NULL
,	NULL
21	NULL
)	NULL
,	NULL
NFAT	NULL
,	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
multicopy	NULL
NFAT	NULL
reporter	NULL
in	NULL
untreated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
,	NULL
but	NULL
had	NULL
a	NULL
marked	NULL
effect	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
«	NULL
CD28	NULL
(	NULL
15-fold	NULL
induction	NULL
of	NULL
NFAT	NULL
activity	NULL
relative	NULL
to	NULL
the	NULL
vector	NULL
alone	NULL
)	NULL
.	NULL

As	NULL
before	NULL
,	NULL
this	NULL
induction	NULL
was	NULL
insensitive	NULL
to	NULL
CsA	NULL
.	NULL

In	NULL
the	NULL
same	NULL
assay	NULL
,	NULL
promoter	NULL
activity	NULL
induced	NULL
by	NULL
PMA	NULL
+	NULL
ionomycin	NULL
was	NULL
abolished	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
overexpressed	NULL
NFAT	NULL
,	NULL
protein	NULL
can	NULL
be	NULL
activated	NULL
through	NULL
a	NULL
CsA-resistant	NULL
pathway	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
IL-2	NULL
promoter	NULL
can	NULL
also	NULL
be	NULL
activated	NULL
by	NULL
a	NULL
CsA-resistant	NULL
pathway	NULL
,	NULL
the	NULL
568-base	NULL
pair	NULL
IL-2	NULL
promoter-B-galactosidase	NULL
reporter	NULL
construct	NULL
(	NULL
designated	NULL
as	NULL
plL2-568	NULL
)	NULL
was	NULL
tested	NULL
in	NULL
the	NULL
transient	NULL
transfection	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Like	NULL
the	NULL
multicopy	NULL
NFAT-TK-Bgal	NULL
construct	NULL
,	NULL
pIL2-568	NULL
showed	NULL
much	NULL
higher	NULL
promoter	NULL
activity	NULL
after	NULL
PMA/	NULL
«	NULL
CD28	NULL
stimulation	NULL
compared	NULL
to	NULL
either	NULL
the	NULL
unstimulated	NULL
control	NULL
or	NULL
to	NULL
PMA	NULL
alone	NULL
(	NULL
panel	NULL
A	NULL
)	NULL
.	NULL

This	NULL
activity	NULL
was	NULL
further	NULL
increased	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
overexpressed	NULL
NFAT	NULL
,	NULL
protein	NULL
(	NULL
panel	NULL
B	NULL
)	NULL
.	NULL

The	NULL
vector	NULL
alone	NULL
did	NULL
not	NULL
have	NULL
any	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
inducible	NULL
promoter	NULL
activity	NULL
was	NULL
completely	NULL
resistant	NULL
to	NULL
CsA	NULL
(	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
)	NULL
,	NULL
whereas	NULL
CsA	NULL
suppressed	NULL
PMA/ionomycin-inducible	NULL
promoter	NULL
activity	NULL
(	NULL
panel	NULL
C	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
the	NULL
promoter	NULL
activity	NULL
induced	NULL
by	NULL
PMA	NULL
+	NULL
«	NULL
CD28	NULL
was	NULL
mediated	NULL
by	NULL
NFAT	NULL
,	NULL
a	NULL
dominant-negative	NULL
NFAT	NULL
,	NULL
protein	NULL
(	NULL
16	NULL
)	NULL
was	NULL
tested	NULL
in	NULL
transient	NULL
transfection	NULL
assay	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
overexpression	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
A	NULL
3	NULL
25	NULL
‘	NULL
C	NULL
pIL2-568+vector	NULL
2	NULL
!	NULL

R	NULL
t.	NULL
plL2-568	NULL
+	NULL
§1s	NULL
_negative	NULL
_________	NULL
]	NULL
<	NULL
4	NULL
as	NULL
o	NULL
&	NULL
3	NULL
eee	NULL
#	NULL
F	NULL
8	NULL
&	NULL
8	NULL
|	NULL
&	NULL
C	NULL
25	NULL
20	NULL
16	NULL
C	NULL
pIL2-568	NULL
+	NULL
NFATe	NULL
+	NULL
&	NULL
vector	NULL
g	NULL
m	NULL
plL2-568	NULL
+	NULL
NFATe	NULL
+	NULL
10	NULL
dominant	NULL
negative	NULL
s	NULL
o	NULL
L	NULL
Activation	NULL
of	NULL
NFAT	NULL
in	NULL
Presence	NULL
of	NULL
CsA	NULL
25	NULL
+	NULL
————	NULL
‘	NULL
20	NULL
C	NULL
pIL2-568	NULL
+	NULL
NFATc	NULL
+	NULL
vector	NULL
15	NULL
m	NULL
pil.2-568	NULL
+	NULL
NFATc	NULL
+	NULL
E	NULL
dominant	NULL
negative	NULL
10	NULL
s	NULL
07	NULL
1	NULL
£o	NULL
|	NULL
&	NULL
D	NULL
»	NULL
18	NULL
16	NULL
14	NULL
a	NULL
CJ	NULL
NFKB-TK-	NULL
&	NULL
gal	NULL
+	NULL
vector	NULL
c	NULL
MNFKE-TK-	NULL
&	NULL
gal	NULL
+	NULL
dominant	NULL
H	NULL
negative	NULL
s	NULL
6	NULL
4	NULL
2	NULL
ol	NULL
Medium	NULL
PMA	NULL
pmwones	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Activation	NULL
of	NULL
an	NULL
IL-2	NULL
promoter-6-galactosidase	NULL
reporter	NULL
gene	NULL
construct	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
.	NULL

A	NULL
,	NULL
the	NULL
pIL2-568	NULL
reporter	NULL
gene	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
along	NULL
with	NULL
expression	NULL
vector	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
expression	NULL
vector	NULL
for	NULL
a	NULL
dominant	NULL
negative	NULL
form	NULL
of	NULL
NFAT	NULL
,	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
was	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
and	NULL
was	NULL
subsequently	NULL
stimulated	NULL
as	NULL
described	NULL
above	NULL
.	NULL

B	NULL
,	NULL
the	NULL
pIL2-568	NULL
reporter	NULL
gene	NULL
along	NULL
with	NULL
the	NULL
NFAT	NULL
,	NULL
expression	NULL
vector	NULL
(	NULL
5	NULL
ug	NULL
each	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
dominant	NULL
negative	NULL
NFAT	NULL
,	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
was	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
that	NULL
were	NULL
subsequently	NULL
stimulated	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
transfected	NULL
plasmids	NULL
was	NULL
normalized	NULL
by	NULL
adding	NULL
the	NULL
empty	NULL
vector	NULL
,	NULL
pBJ5	NULL
.	NULL

C	NULL
,	NULL
similar	NULL
experiment	NULL
as	NULL
B	NULL
except	NULL
the	NULL
stimulation	NULL
was	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

D	NULL
,	NULL
the	NULL
NFxB-TK-Bgal	NULL
reporter	NULL
gene	NULL
was	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
along	NULL
with	NULL
the	NULL
expression	NULL
vector	NULL
for	NULL
the	NULL
dominant	NULL
negative	NULL
NFAT	NULL
,	NULL
(	NULL
5	NULL
ug	NULL
each	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
subsequently	NULL
stimulated	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1.	NULL
of	NULL
the	NULL
dominant	NULL
negative	NULL
resulted	NULL
in	NULL
70-80	NULL
%	NULL
inhibition	NULL
of	NULL
PMA/CD28-inducible	NULL
promoter	NULL
activity	NULL
,	NULL
but	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
the	NULL
dominant	NULL
negative	NULL
NFAT	NULL
,	NULL
protein	NULL
had	NULL
very	NULL
little	NULL
effect	NULL
on	NULL
an	NULL
NFxB-TK-Bgal	NULL
reporter	NULL
construct	NULL
(	NULL
panel	NULL
D	NULL
)	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
the	NULL
IL-2	NULL
promoter	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
PMA/	NULL
eCD28	NULL
in	NULL
a	NULL
CsA-resistant	NULL
manner	NULL
,	NULL
and	NULL
that	NULL
this	NULL
activation	NULL
is	NULL
mediated	NULL
by	NULL
NFAT	NULL
.	NULL

Induction	NULL
of	NULL
an	NULL
NFAT	NULL
Complex	NULL
by	NULL
PMA	NULL
and	NULL
«	NULL
CD28	NULL
in	NULL
the	NULL
Presence	NULL
of	NULL
CsA-Induction	NULL
of	NULL
NFAT	NULL
activity	NULL
implies	NULL
induction	NULL
of	NULL
the	NULL
DNA-binding	NULL
NFAT	NULL
complex	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
stimulated	NULL
cells	NULL
.	NULL

To	NULL
look	NULL
for	NULL
this	NULL
complex	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
the	NULL
IL-2-distal	NULL
NFAT	NULL
site	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
nuclear	NULL
extract	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
«	NULL
CD28	NULL
showed	NULL
an	NULL
inducible	NULL
complex	NULL
(	NULL
compare	NULL
lane	NULL
1	NULL
with	NULL
2	NULL
)	NULL
which	NULL
comigrated	NULL
with	NULL
the	NULL
PMA/ionomycin-inducible	NULL
complex	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
.	NULL

The	NULL
PMA/aCD28-inducible	NULL
complex	NULL
was	NULL
resistant	NULL
to	NULL
CsA	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
PMA/	NULL
ionomycin-induced	NULL
complex	NULL
was	NULL
sensitive	NULL
to	NULL
CsA	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
.	NULL

The	NULL
PMA/aCD28-inducible	NULL
complex	NULL
was	NULL
specific	NULL
to	NULL
the	NULL
probe	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
competition	NULL
assay	NULL
with	NULL
specific	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
and	NULL
nonspecific	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
competitors	NULL
.	NULL

The	NULL
complex	NULL
was	NULL
completely	NULL
blocked	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
consensus	NULL
API	NULL
site	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
indicating	NULL
the	NULL
involvement	NULL
of	NULL
AP1	NULL
in	NULL
the	NULL
inducible	NULL
complex	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
the	NULL
inducible	NULL
complex	NULL
contained	NULL
NFAT	NULL
protein	NULL
,	NULL
we	NULL
performed	NULL
supershift	NULL
analysis	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
antiserum	NULL
raised	NULL
against	NULL
a	NULL
peptide	NULL
that	NULL
is	NULL
common	NULL
to	NULL
all	NULL
NFAT	NULL
proteins	NULL
was	NULL
able	NULL
to	NULL
block	NULL
the	NULL
inducible	NULL
complex	NULL
(	NULL
Zane	NULL
2	NULL
)	NULL
.	NULL

Another	NULL
antiserum	NULL
raised	NULL
against	NULL
an	NULL
NFAT	NULL
,	NULL
-specific	NULL
epitope	NULL
showed	NULL
a	NULL
partial	NULL
supershift	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
,	NULL
whereas	NULL
an	NULL
irrelevant	NULL
antiserum	NULL
failed	NULL
to	NULL
react	NULL
with	NULL
the	NULL
complex	NULL
(	NULL
Zane	NULL
3	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
a	NULL
PMA/aCD28-inducible	NULL
complex	NULL
was	NULL
also	NULL
present	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
compare	NULL
lane	NULL
2	NULL
with	NULL
1	NULL
)	NULL
.	NULL

As	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
this	NULL
inducible	NULL
complex	NULL
was	NULL
insensitive	NULL
to	NULL
CsA	NULL
,	NULL
whereas	NULL
the	NULL
PMA/ionomycin-inducible	NULL
complex	NULL
was	NULL
sensitive	NULL
to	NULL
CsA	NULL
(	NULL
compare	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
)	NULL
.	NULL

Competition	NULL
assays	NULL
and	NULL
supershift	NULL
analysis	NULL
revealed	NULL
that	NULL
the	NULL
PMA/aCD28	NULL
complex	NULL
contained	NULL
NFAT	NULL
protein	NULL
as	NULL
well	NULL
as	NULL
the	NULL
members	NULL
of	NULL
the	NULL
AP1	NULL
family	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
in	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
the	NULL
NFAT	NULL
DNA-binding	NULL
complex	NULL
can	NULL
be	NULL
induced	NULL
in	NULL
a	NULL
CsA-resistant	NULL
manner	NULL
by	NULL
PMA/aCD28	NULL
stimulation	NULL
.	NULL

Production	NULL
of	NULL
IL-2	NULL
by	NULL
Peripheral	NULL
Blood	NULL
T	NULL
Cells	NULL
after	NULL
Stimulation	NULL
with	NULL
PMA	NULL
and	NULL
«	NULL
CD28	NULL
in	NULL
the	NULL
Presence	NULL
of	NULL
CsA-It	NULL
has	NULL
been	NULL
shown	NULL
previously	NULL
that	NULL
treatment	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
with	NULL
PMA	NULL
+	NULL
«	NULL
CD28	NULL
leads	NULL
to	NULL
IL2	NULL
production	NULL
,	NULL
and	NULL
that	NULL
this	NULL
induction	NULL
is	NULL
largely	NULL
resistant	NULL
to	NULL
CsA	NULL
(	NULL
10	NULL
,	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

We	NULL
expected	NULL
this	NULL
to	NULL
be	NULL
true	NULL
under	NULL
our	NULL
conditions	NULL
as	NULL
well	NULL
,	NULL
since	NULL
reporter	NULL
assays	NULL
showed	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
EMSA	NULL
showed	NULL
induction	NULL
of	NULL
the	NULL
NFAT	NULL
complex	NULL
.	NULL

To	NULL
test	NULL
for	NULL
IL-2	NULL
production	NULL
,	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
aCD28	NULL
for	NULL
18	NULL
h	NULL
with	NULL
or	NULL
without	NULL
CsA	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
stimulation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CsA	NULL
resulted	NULL
in	NULL
the	NULL
production	NULL
of	NULL
over	NULL
200	NULL
units/ml	NULL
of	NULL
IL-2	NULL
;	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
,	NULL
IL-2	NULL
was	NULL
produced	NULL
at	NULL
70-85	NULL
%	NULL
of	NULL
this	NULL
level	NULL
(	NULL
the	NULL
slight	NULL
drop	NULL
may	NULL
be	NULL
due	NULL
to	NULL
toxic	NULL
effects	NULL
from	NULL
the	NULL
high	NULL
concentration	NULL
of	NULL
drug	NULL
used	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
CsA	NULL
drastically	NULL
reduced	NULL
IL-2	NULL
production	NULL
(	NULL
to	NULL
7	NULL
%	NULL
of	NULL
the	NULL
level	NULL
produced	NULL
without	NULL
CsA	NULL
)	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
+	NULL
ionomycin	NULL
.	NULL

In	NULL
absolute	NULL
terms	NULL
as	NULL
well	NULL
,	NULL
CsA-resistant	NULL
IL-2	NULL
levels	NULL
are	NULL
substantially	NULL
higher	NULL
in	NULL
PMA-CD28	NULL
stimulated	NULL
cells	NULL
(	NULL
140	NULL
units/ml	NULL
)	NULL
than	NULL
in	NULL
PMA/ionomycin-treated	NULL
cells	NULL
(	NULL
24	NULL
units/ml	NULL
)	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
the	NULL
physiological	NULL
significance	NULL
of	NULL
CsA-resistant	NULL
NFAT	NULL
activation	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Activation	NULL
of	NULL
NFAT	NULL
in	NULL
Presence	NULL
of	NULL
CsA	NULL
77083	NULL
A	NULL
<	NULL
a	NULL
B	NULL
o	NULL
w	NULL
co	NULL
<	NULL
O	NULL
®	NULL
O	NULL
2	NULL
Cf	NULL
5	NULL
§	NULL
g	NULL
f	NULL
o	NULL
o	NULL
a	NULL
.	NULL

§	NULL
3	NULL
3	NULL
<	NULL
S	NULL
50	NULL
g	NULL
o	NULL
d	NULL
IS	NULL
id	NULL
i	NULL
=o	NULL
g	NULL
w.	NULL
u	NULL
.	NULL

$	NULL
E	NULL
s	NULL
s	NULL
s	NULL
9°	NULL
a	NULL
.	NULL

Z	NULL
y	NULL
Z	NULL
=	NULL
o	NULL
a	NULL
a	NULL
aA	NULL
#	NULL
0	NULL
<	NULL
0	NULL
Z	NULL
1	NULL
Cs	NULL
&	NULL
G	NULL
te	NULL
#	NULL
»	NULL
(	NULL
ip	NULL
»	NULL
==	NULL
ao	NULL
n	NULL
gan	NULL
#	NULL
>	NULL
wa	NULL
as	NULL
a=	NULL
wou	NULL
whee	NULL
o	NULL
10	NULL
20	NULL
3	NULL
4	NULL
C	NULL
4	NULL
<	NULL
o	NULL
w	NULL
s	NULL
-	NULL
&	NULL
209g	NULL
a	NULL
A	NULL
$	NULL
g	NULL
E	NULL
Q	NULL
9	NULL
PhD—go	NULL
3	NULL
S	NULL
S	NULL
<	NULL
=	NULL
4	NULL
3	NULL
z	NULL
C	NULL
<	NULL
I	NULL
Sog	NULL
-	NULL
g	NULL
&	NULL
&	NULL
<	NULL
0	NULL
4	NULL
$	NULL
0	NULL
s	NULL
s	NULL
9	NULL
a	NULL
2	NULL
z	NULL
Z	NULL
,	NULL
E	NULL
E	NULL
=	NULL
a	NULL
a	NULL
#	NULL
<	NULL
Z2	NULL
c	NULL
s	NULL
2	NULL
a	NULL
a	NULL
e	NULL
%	NULL
o	NULL
**	NULL
``	NULL
I	NULL
=p	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

EMSA	NULL
demonstrating	NULL
the	NULL
presence	NULL
of	NULL
inducible	NULL
NFAT	NULL
complex	NULL
.	NULL

A	NULL
,	NULL
EMSA	NULL
with	NULL
*°P-labeled	NULL
IL-2	NULL
distal	NULL
NFAT	NULL
site	NULL
using	NULL
nuclear	NULL
extracts	NULL
of	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
medium	NULL
(	NULL
Fane	NULL
1	NULL
)	NULL
,	NULL
PMA/CD28	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
PMA/CD28/CsA	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
PMA/ionomycin	NULL
(	NULL
PMA	NULL
/Iono	NULL
.	NULL

;	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
and	NULL
PMA/ionomycin/CsA	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
.	NULL

Lanes	NULL
6	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
represent	NULL
competition	NULL
analysis	NULL
of	NULL
PMA/CD28-treated	NULL
nuclear	NULL
extracts	NULL
using	NULL
unlabeled	NULL
specific	NULL
competitor	NULL
(	NULL
S.C.	NULL
)	NULL
,	NULL
API	NULL
oligonucleotide	NULL
,	NULL
and	NULL
SP1	NULL
oligonucleotide	NULL
as	NULL
a	NULL
nonspecific	NULL
competitor	NULL
(	NULL
N.C.	NULL
)	NULL
.	NULL

B	NULL
,	NULL
supershift	NULL
analysis	NULL
of	NULL
PMA/CD28-inducible	NULL
complex	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
using	NULL
eNFAT	NULL
(	NULL
Zane	NULL
2	NULL
)	NULL
,	NULL
OlNFATp	NULL
{	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
and	NULL
an	NULL
irrelevant	NULL
antiserum	NULL
(	NULL
IR	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

C	NULL
,	NULL
EMSA	NULL
with	NULL
labeled	NULL
IL-2	NULL
NFAT	NULL
site	NULL
using	NULL
nuclear	NULL
extracts	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
treated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
,	NULL
PMA/CD28	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
PMA/CD28/CsA	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
PMA/ionomycin	NULL
(	NULL
Fane	NULL
10	NULL
)	NULL
,	NULL
and	NULL
PMA/onomycin/CsA	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
.	NULL

Lanes	NULL
4	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
represent	NULL
competition	NULL
analysis	NULL
of	NULL
PMA/CD28-treated	NULL
nuclear	NULL
extracts	NULL
using	NULL
unlabeled	NULL
specific	NULL
competitor	NULL
(	NULL
S.C.	NULL
)	NULL
,	NULL
API	NULL
site	NULL
,	NULL
and	NULL
SP1	NULL
as	NULL
a	NULL
nonspecific	NULL
competitor	NULL
(	NULL
N.C.	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Lanes	NULL
7	NULL
,	NULL
8	NULL
,	NULL
and	NULL
9	NULL
represent	NULL
supershift	NULL
analysis	NULL
of	NULL
PMA/CD28-inducible	NULL
complex	NULL
using	NULL
«	NULL
NFAT	NULL
,	NULL
NFAT	NULL
,	NULL
and	NULL
an	NULL
irrelevant	NULL
antiserum	NULL
(	NULL
ZR	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

350	NULL
300	NULL
'EiSeries	NULL
If	NULL
Series2	NULL
250	NULL
_	NULL
ben	NULL
.	NULL

Medium	NULL
PMA/CD28	NULL
PMA/CD28/CsA	NULL
P.J	NULL
.	NULL

P.L/ICsA	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Production	NULL
of	NULL
IL-2	NULL
by	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

Peripheral	NULL
blood	NULL
T	NULL
cells	NULL
isolated	NULL
from	NULL
two	NULL
different	NULL
donors	NULL
were	NULL
stimulated	NULL
with	NULL
medium	NULL
alone	NULL
,	NULL
PMA/CD28	NULL
,	NULL
PMA/CD28/CsA	NULL
,	NULL
PMA/ionomycin	NULL
,	NULL
and	NULL
PMA/ionomycin/CsA	NULL
for	NULL
24	NULL
h.	NULL
IL-2	NULL
secreted	NULL
into	NULL
the	NULL
medium	NULL
was	NULL
measured	NULL
by	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
.	NULL

CsA	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cells	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
stimulation	NULL
.	NULL

DISCUSSION	NULL
Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
immunosuppressive	NULL
drug	NULL
CsA	NULL
drastically	NULL
inhibits	NULL
,	NULL
but	NULL
does	NULL
not	NULL
completely	NULL
block	NULL
,	NULL
IL-2	NULL
production	NULL
following	NULL
stimulation	NULL
by	NULL
«	NULL
CD3	NULL
and	NULL
eCD28	NULL
(	NULL
10	NULL
)	NULL
.	NULL

The	NULL
drug-resistant	NULL
activity	NULL
can	NULL
most	NULL
likely	NULL
be	NULL
traced	NULL
to	NULL
the	NULL
CD28	NULL
signaling	NULL
pathway	NULL
,	NULL
since	NULL
stimulation	NULL
of	NULL
cells	NULL
with	NULL
PMA	NULL
(	NULL
to	NULL
mimic	NULL
the	NULL
Ca**-independent	NULL
aspects	NULL
of	NULL
«	NULL
CD3	NULL
signaling	NULL
)	NULL
and	NULL
«	NULL
CD28	NULL
is	NULL
entirely	NULL
resistant	NULL
to	NULL
CsA	NULL
(	NULL
10	NULL
)	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
IL-2	NULL
is	NULL
produced	NULL
at	NULL
significant	NULL
levels	NULL
in	NULL
the	NULL
continued	NULL
presence	NULL
of	NULL
CsA	NULL
or	NULL
FK506	NULL
.	NULL

Since	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT	NULL
is	NULL
required	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
,	NULL
these	NULL
results	NULL
imply	NULL
that	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
well-known	NULL
Ca**-dependent	NULL
pathway	NULL
,	NULL
NFAT	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
a	NULL
CsA-resistant	NULL
pathway	NULL
.	NULL

Data	NULL
presented	NULL
here	NULL
show	NULL
that	NULL
this	NULL
is	NULL
the	NULL
case	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
NFAT	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
reporter	NULL
gene	NULL
constructs	NULL
(	NULL
both	NULL
NFAT-TK-Bgal	NULL
and	NULL
pIL2-568	NULL
)	NULL
after	NULL
PMA/	NULL
«	NULL
CD28	NULL
treatment	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
was	NULL
demonstrated	NULL
by	NULL
the	NULL
facts	NULL
that	NULL
(	NULL
i	NULL
)	NULL
overexpressed	NULL
wild	NULL
type	NULL
NFAT	NULL
augmented	NULL
reporter	NULL
activity	NULL
only	NULL
after	NULL
PMA/aCD28	NULL
stimulation	NULL
,	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
inducible	NULL
reporter	NULL
activity	NULL
was	NULL
essentially	NULL
eliminated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
mutant	NULL
of	NULL
NFAT	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
NFAT	NULL
in	NULL
the	NULL
PMA/aCD28-inducible	NULL
DNA-protein	NULL
complexes	NULL
was	NULL
also	NULL
demonstrated	NULL
by	NULL
the	NULL
supershift	NULL
assays	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
the	NULL
transient	NULL
transfection	NULL
assays	NULL
,	NULL
the	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
also	NULL
shown	NULL
to	NULL
produce	NULL
IL-2	NULL
after	NULL
PMA/	NULL
«	NULL
CD28	NULL
treatment	NULL
,	NULL
and	NULL
this	NULL
production	NULL
was	NULL
resistant	NULL
to	NULL
CsA	NULL
.	NULL

The	NULL
established	NULL
pathway	NULL
for	NULL
NFAT	NULL
activation	NULL
involves	NULL
Ca**	NULL
dependent	NULL
activation	NULL
of	NULL
the	NULL
serine-threonine	NULL
phosphatase	NULL
cal-cineurin	NULL
.	NULL

Subsequent	NULL
dephosphorylation	NULL
of	NULL
NFAT	NULL
leads	NULL
to	NULL
its	NULL
nuclear	NULL
translocation	NULL
and	NULL
,	NULL
in	NULL
conjunction	NULL
with	NULL
AP-1	NULL
,	NULL
DNA	NULL
binding	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
here	NULL
suggest	NULL
an	NULL
alternate	NULL
pathway	NULL
for	NULL
NFAT	NULL
activation	NULL
that	NULL
is	NULL
calcineurin	NULL
independent	NULL
.	NULL

Since	NULL
dephosphorylation	NULL
of	NULL
NFAT	NULL
appears	NULL
to	NULL
be	NULL
necessary	NULL
for	NULL
its	NULL
activity	NULL
,	NULL
a	NULL
different	NULL
phosphatase	NULL
must	NULL
be	NULL
involved	NULL
in	NULL
this	NULL
pathway	NULL
.	NULL

A	NULL
candidate	NULL
second	NULL
messenger	NULL
(	NULL
instead	NULL
of	NULL
Ca**	NULL
)	NULL
is	NULL
ceram-ide	NULL
,	NULL
which	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
CD28	NULL
signaling	NULL
(	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
serine/threonine	NULL
phosphatase	NULL
has	NULL
been	NULL
reported	NULL
recently	NULL
that	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
sphingomyelin	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
7704	NULL
pathway	NULL
(	NULL
24	NULL
)	NULL
.	NULL

It	NULL
is	NULL
an	NULL
attractive	NULL
hypothesis	NULL
that	NULL
this	NULL
or	NULL
another	NULL
ceramide-induced	NULL
phosphatase	NULL
can	NULL
lead	NULL
to	NULL
NFAT	NULL
activation	NULL
in	NULL
a	NULL
CsA-resistant	NULL
manner	NULL
.	NULL

This	NULL
idea	NULL
is	NULL
currently	NULL
being	NULL
tested	NULL
.	NULL

The	NULL
present	NULL
finding	NULL
may	NULL
explain	NULL
the	NULL
ineffectiveness	NULL
of	NULL
CsA	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
graft	NULL
versus	NULL
host	NULL
disease	NULL
following	NULL
allogenic	NULL
bone	NULL
marrow	NULL
transplantation	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
cytotoxic	NULL
T	NULL
cells	NULL
thought	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
graft	NULL
versus	NULL
host	NULL
disease	NULL
(	NULL
27	NULL
)	NULL
express	NULL
CD28	NULL
on	NULL
their	NULL
surface	NULL
and	NULL
are	NULL
capable	NULL
of	NULL
producing	NULL
cytokines	NULL
responsible	NULL
for	NULL
immune	NULL
reaction	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Dr.	NULL
Scott	NULL
Durum	NULL
for	NULL
his	NULL
critical	NULL
com-ments	NULL
,	NULL
William	NULL
Bere	NULL
for	NULL
technical	NULL
assistance	NULL
,	NULL
Susan	NULL
Charbonneau	NULL
and	NULL
Joyce	NULL
Vincent	NULL
for	NULL
their	NULL
secretarial	NULL
and	NULL
editorial	NULL
assistance	NULL
,	NULL
and	NULL
the	NULL
Cytokine	NULL
Testing	NULL
Laboratory	NULL
for	NULL
their	NULL
help	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Shaw	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Replogle	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Belagaje	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
1715-1724	NULL
2	NULL
.	NULL

Shaw	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Utz	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Toole	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
241	NULL
,	NULL
202-205	NULL
3	NULL
.	NULL

Rooney	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Sun	NULL
,	NULL
Y.-L.	NULL
,	NULL
Glimscher	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
and	NULL
Hoey	NULL
,	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
6299-6310	NULL
4	NULL
.	NULL

Flanagan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Corthesy	NULL
,	NULL
B.	NULL
,	NULL
Bram	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
352	NULL
,	NULL
803-807	NULL
5	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Perrino	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Soderling	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
3747-3752	NULL
6	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
856	NULL
,	NULL
801-804	NULL
.	NULL

Clipstone	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
857	NULL
,	NULL
695-697	NULL
.	NULL

Bram	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Hung	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
Martin	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
4760-4769	NULL
go	NULL
~	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

Activation	NULL
of	NULL
NFAT	NULL
in	NULL
Presence	NULL
of	NULL
CsA	NULL
9	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Bluestone	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
15	NULL
,	NULL
321-331	NULL
Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Emerson	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Leiden	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

86	NULL
,	NULL
1333-1337	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Stella	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
244	NULL
,	NULL
339-348	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Gillespie	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
4472-4481	NULL
van	NULL
Lier	NULL
,	NULL
R.	NULL
A.	NULL
W.	NULL
,	NULL
Brouwer	NULL
,	NULL
M.	NULL
,	NULL
De	NULL
Groot	NULL
,	NULL
E.	NULL
,	NULL
Kramer	NULL
,	NULL
I.	NULL
,	NULL
Aarden	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
and	NULL
Verhoeven	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

21	NULL
,	NULL
1775-1778	NULL
Luckow	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Schiitz	NULL
,	NULL
G.	NULL
(	NULL
1987	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

15	NULL
,	NULL
5490	NULL
Penix	NULL
,	NULL
L.	NULL
,	NULL
Weaver	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Pang	NULL
,	NULL
Y.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
and	NULL
Wilson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178	NULL
,	NULL
1483-1496	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Ho	NULL
,	NULL
S.	NULL
,	NULL
Chen	NULL
,	NULL
L.	NULL
,	NULL
Thomas	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Timmerman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Admon	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
869	NULL
,	NULL
497-502	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Morgan	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165	NULL
,	NULL
395-407	NULL
Eustice	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
Feldman	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Colberg-Poley	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Buckery	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Neubauer	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
BioTechniques	NULL
11	NULL
,	NULL
739-748	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Ye	NULL
,	NULL
J.	NULL
,	NULL
Franco	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Wiltrout	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Rie	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
and	NULL
Komaschlies	NULL
,	NULL
K.	NULL
L.	NULL
(	NULL
1994	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

54	NULL
,	NULL
2969-2972	NULL
Truneh	NULL
,	NULL
A.	NULL
,	NULL
Albert	NULL
,	NULL
F.	NULL
,	NULL
Golstein	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Schmitt-Verhulst	NULL
,	NULL
A.-M.	NULL
(	NULL
1985	NULL
)	NULL
Nature	NULL
813	NULL
,	NULL
318-320	NULL
Hoey	NULL
,	NULL
T.	NULL
,	NULL
Sun	NULL
,	NULL
Y.-L.	NULL
,	NULL
Williamson	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Xu	NULL
,	NULL
X	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunity	NULL
2	NULL
,	NULL
461-472	NULL
Chan	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Ochi	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25	NULL
,	NULL
1999-2004	NULL
Boucher	NULL
,	NULL
L.-M.	NULL
,	NULL
Wiegmann	NULL
,	NULL
K.	NULL
,	NULL
Fiitterer	NULL
,	NULL
K.	NULL
,	NULL
Pfeffer	NULL
,	NULL
K.	NULL
,	NULL
Machleidt	NULL
,	NULL
T.	NULL
,	NULL
Schiitze	NULL
,	NULL
S.	NULL
,	NULL
Mak	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
and	NULL
Kronke	NULL
,	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
2059-2068	NULL
Wolff	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Dobrowsky	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
Bielawska	NULL
,	NULL
A.	NULL
,	NULL
Obeid	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
and	NULL
Hannun	NULL
,	NULL
Y	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
19605-19609	NULL
Storb	NULL
,	NULL
R.	NULL
,	NULL
Deeg	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Whitehead	NULL
,	NULL
J.	NULL
,	NULL
Farewell	NULL
,	NULL
V.	NULL
,	NULL
Appelbaum	NULL
,	NULL
F.	NULL
R.	NULL
,	NULL
Beatty	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Besinger	NULL
,	NULL
W.	NULL
,	NULL
Buckner	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Clift	NULL
,	NULL
R.	NULL
,	NULL
Hansen	NULL
,	NULL
J.	NULL
,	NULL
Hill	NULL
,	NULL
R.	NULL
,	NULL
Longton	NULL
,	NULL
G.	NULL
,	NULL
Lum	NULL
,	NULL
L.	NULL
,	NULL
Martin	NULL
,	NULL
P.	NULL
,	NULL
McGuffin	NULL
,	NULL
R.	NULL
,	NULL
Sanders	NULL
,	NULL
J.	NULL
,	NULL
Singer	NULL
,	NULL
J.	NULL
,	NULL
Stewart	NULL
,	NULL
P.	NULL
,	NULL
Sullivan	NULL
,	NULL
K.	NULL
,	NULL
Witherspoon	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Thomas	NULL
,	NULL
E.	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Blood	NULL
68	NULL
,	NULL
119-125	NULL
Pai	NULL
,	NULL
S.-Y	NULL
.	NULL

,	NULL
Fruman	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Leong	NULL
,	NULL
T.	NULL
,	NULL
Neuberg	NULL
,	NULL
D.	NULL
,	NULL
Rosano	NULL
,	NULL
T.	NULL
G.	NULL
,	NULL
McGarigle	NULL
,	NULL
C.	NULL
,	NULL
Antin	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Bierer	NULL
,	NULL
B.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
Blood	NULL
84	NULL
,	NULL
3974-3979	NULL
Storb	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Thomas	NULL
,	NULL
E.	NULL
D.	NULL
(	NULL
1985	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

88	NULL
,	NULL
215-238	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Activation	NULL
of	NULL
Nuclear	NULL
Factor	NULL
of	NULL
Activated	NULL
T	NULL
Cells	NULL
in	NULL
a	NULL
Cyclosporin	NULL
A-resistant	NULL
Pathway	NULL
Paritosh	NULL
Ghosh	NULL
,	NULL
Antonio	NULL
Sica	NULL
,	NULL
Marco	NULL
Cippitelli	NULL
,	NULL
Jeff	NULL
Subleski	NULL
,	NULL
Riitta	NULL
Lahesmaa	NULL
,	NULL
Howard	NULL
A	NULL
.	NULL

Young	NULL
and	NULL
Nancy	NULL
R.	NULL
Rice	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1996	NULL
,	NULL
271:7700-7704.	NULL
doi	NULL
:	NULL
10.1074/jb0.271.13.7700	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/271/13/7700	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
27	NULL
references	NULL
,	NULL
15	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
3/7700	NULL
full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
4q	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL

